Literature DB >> 32184340

Modeling disease trajectory in Duchenne muscular dystrophy.

William D Rooney1, Yosef A Berlow2, William T Triplett2, Sean C Forbes2, Rebecca J Willcocks2, Dah-Jyuu Wang2, Ishu Arpan2, Harneet Arora2, Claudia Senesac2, Donovan J Lott2, Gihan Tennekoon2, Richard Finkel2, Barry S Russman2, Erika L Finanger2, Saptarshi Chakraborty2, Elliott O'Brien2, Brendan Moloney2, Alison Barnard2, H Lee Sweeney2, Michael J Daniels2, Glenn A Walter2, Krista Vandenborne2.   

Abstract

OBJECTIVE: To quantify disease progression in individuals with Duchenne muscular dystrophy (DMD) using magnetic resonance biomarkers of leg muscles.
METHODS: MRI and magnetic resonance spectroscopy (MRS) biomarkers were acquired from 104 participants with DMD and 51 healthy controls using a prospective observational study design with patients with DMD followed up yearly for up to 6 years. Fat fractions (FFs) in vastus lateralis and soleus muscles were determined with 1H MRS. MRI quantitative T2 (qT2) values were measured for 3 muscles of the upper leg and 5 muscles of the lower leg. Longitudinal changes in biomarkers were modeled with a cumulative distribution function using a nonlinear mixed-effects approach.
RESULTS: MRS FF and MRI qT2 increased with DMD disease duration, with the progression time constants differing markedly between individuals and across muscles. The average age at half-maximal muscle involvement (μ) occurred 4.8 years earlier in vastus lateralis than soleus, and these measures were strongly associated with loss-of-ambulation age. Corticosteroid treatment was found to delay μ by 2.5 years on average across muscles, although there were marked differences between muscles with more slowly progressing muscles showing larger delay.
CONCLUSIONS: MRS FF and MRI qT2 provide sensitive noninvasive measures of DMD progression. Modeling changes in these biomarkers across multiple muscles can be used to detect and monitor the therapeutic effects of corticosteroids on disease progression and to provide prognostic information on functional outcomes. This modeling approach provides a method to transform these MRI biomarkers into well-understood metrics, allowing concise summaries of DMD disease progression at individual and population levels. CLINICALTRIALSGOV IDENTIFIER: NCT01484678.
© 2020 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32184340      PMCID: PMC7251517          DOI: 10.1212/WNL.0000000000009244

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  31 in total

1.  Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study.

Authors:  Craig M McDonald; Erik K Henricson; Richard T Abresch; Tina Duong; Nanette C Joyce; Fengming Hu; Paula R Clemens; Eric P Hoffman; Avital Cnaan; Heather Gordish-Dressman
Journal:  Lancet       Date:  2017-11-22       Impact factor: 79.321

2.  Human soleus muscle: a comparison of fiber composition and enzyme activities with other leg muscles.

Authors:  P D Gollnick; B Sjödin; J Karlsson; E Jansson; B Saltin
Journal:  Pflugers Arch       Date:  1974-04-22       Impact factor: 3.657

3.  Dystrophin: the protein product of the Duchenne muscular dystrophy locus.

Authors:  E P Hoffman; R H Brown; L M Kunkel
Journal:  Cell       Date:  1987-12-24       Impact factor: 41.582

Review 4.  A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy.

Authors:  Jean K Mah; Lawrence Korngut; Jonathan Dykeman; Lundy Day; Tamara Pringsheim; Nathalie Jette
Journal:  Neuromuscul Disord       Date:  2014-03-22       Impact factor: 4.296

5.  Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS.

Authors:  P J Pouwels; J Frahm
Journal:  Magn Reson Med       Date:  1998-01       Impact factor: 4.668

Review 6.  The muscular dystrophies.

Authors:  Alan E H Emery
Journal:  Lancet       Date:  2002-02-23       Impact factor: 79.321

7.  Quantitative MRI and loss of free ambulation in Duchenne muscular dystrophy.

Authors:  Arne Fischmann; Patricia Hafner; Monika Gloor; Maurice Schmid; Andrea Klein; Urs Pohlman; Tanja Waltz; Rocio Gonzalez; Tanja Haas; Oliver Bieri; Dirk Fischer
Journal:  J Neurol       Date:  2012-11-09       Impact factor: 4.849

8.  MRI quantifies neuromuscular disease progression.

Authors:  Sean C Forbes; Rebecca J Willcocks; William D Rooney; Glenn A Walter; Krista Vandenborne
Journal:  Lancet Neurol       Date:  2015-11-06       Impact factor: 44.182

9.  Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy.

Authors:  Robert C Griggs; J Phillip Miller; Cheryl R Greenberg; Darcy L Fehlings; Alan Pestronk; Jerry R Mendell; Richard T Moxley; Wendy King; John T Kissel; Valerie Cwik; Michel Vanasse; Julaine M Florence; Shree Pandya; Jordan S Dubow; James M Meyer
Journal:  Neurology       Date:  2016-08-26       Impact factor: 9.910

10.  Skeletal muscle magnetic resonance biomarkers correlate with function and sentinel events in Duchenne muscular dystrophy.

Authors:  Alison M Barnard; Rebecca J Willcocks; Erika L Finanger; Michael J Daniels; William T Triplett; William D Rooney; Donovan J Lott; Sean C Forbes; Dah-Jyuu Wang; Claudia R Senesac; Ann T Harrington; Richard S Finkel; Barry S Russman; Barry J Byrne; Gihan I Tennekoon; Glenn A Walter; H Lee Sweeney; Krista Vandenborne
Journal:  PLoS One       Date:  2018-03-19       Impact factor: 3.240

View more
  19 in total

1.  Characterizing Expiratory Respiratory Muscle Degeneration in Duchenne Muscular Dystrophy Using MRI.

Authors:  Alison M Barnard; Donovan J Lott; Abhinandan Batra; William T Triplett; Rebecca J Willcocks; Sean C Forbes; William D Rooney; Michael J Daniels; Barbara K Smith; Krista Vandenborne; Glenn A Walter
Journal:  Chest       Date:  2021-09-15       Impact factor: 10.262

2.  Muscle quantitative MRI as a novel biomarker in hereditary transthyretin amyloidosis with polyneuropathy: a cross-sectional study.

Authors:  Elisa Vegezzi; Andrea Cortese; Laura Obici; Anna Pichiecchio; Niels Bergsland; Roberta Mussinelli; Matteo Paoletti; Francesca Solazzo; Riccardo Currò; Lucia Ascagni; Ilaria Callegari; Ilaria Quartesan; Alessandro Lozza; Xeni Deligianni; Francesco Santini; Enrico Marchioni; Giuseppe Cosentino; Enrico Alfonsi; Cristina Tassorelli; Stefano Bastianello; Giampaolo Merlini; Giovanni Palladini
Journal:  J Neurol       Date:  2022-09-06       Impact factor: 6.682

3.  Development of Contractures in DMD in Relation to MRI-Determined Muscle Quality and Ambulatory Function.

Authors:  Rebecca J Willcocks; Alison M Barnard; Ryan J Wortman; Claudia R Senesac; Donovan J Lott; Ann T Harrington; Kirsten L Zilke; Sean C Forbes; William D Rooney; Dah-Jyuu Wang; Erika L Finanger; Gihan I Tennekoon; Michael J Daniels; William T Triplett; Glenn A Walter; Krista Vandenborne
Journal:  J Neuromuscul Dis       Date:  2022

4.  Step Activity Monitoring in Boys with Duchenne Muscular Dystrophy and its Correlation with Magnetic Resonance Measures and Functional Performance.

Authors:  Kavya S Nair; Donovan J Lott; Sean C Forbes; Alison M Barnard; Rebecca J Willcocks; Claudia R Senesac; Michael J Daniels; Ann T Harrington; Gihan I Tennekoon; Kirsten Zilke; Erika L Finanger; Richard S Finkel; William D Rooney; Glenn A Walter; Krista Vandenborne
Journal:  J Neuromuscul Dis       Date:  2022

5.  Postcontractile blood oxygenation level-dependent (BOLD) response in Duchenne muscular dystrophy.

Authors:  Christopher Lopez; Tanja Taivassalo; Maria G Berru; Andres Saavedra; Hannah C Rasmussen; Abhinandan Batra; Harneet Arora; Alex M Roetzheim; Glenn A Walter; Krista Vandenborne; Sean C Forbes
Journal:  J Appl Physiol (1985)       Date:  2021-05-20

6.  Baseline fat fraction is a strong predictor of disease progression in Becker muscular dystrophy.

Authors:  Thom T J Veeger; Nienke M van de Velde; Kevin R Keene; Erik H Niks; Melissa T Hooijmans; Andrew G Webb; Jurriaan H de Groot; Hermien E Kan
Journal:  NMR Biomed       Date:  2022-02-05       Impact factor: 4.478

7.  Muscle architecture is associated with muscle fat replacement in Duchenne and Becker muscular dystrophies.

Authors:  Thom T J Veeger; Erik W van Zwet; Diaa Al Mohamad; Karin J Naarding; Nienke M van de Velde; Melissa T Hooijmans; Andrew G Webb; Erik H Niks; Jurriaan H de Groot; Hermien E Kan
Journal:  Muscle Nerve       Date:  2021-08-25       Impact factor: 3.852

8.  miR-486 is essential for muscle function and suppresses a dystrophic transcriptome.

Authors:  Adrienne Samani; Rylie M Hightower; Andrea L Reid; Katherine G English; Michael A Lopez; J Scott Doyle; Michael J Conklin; David A Schneider; Marcas M Bamman; Jeffrey J Widrick; David K Crossman; Min Xie; David Jee; Eric C Lai; Matthew S Alexander
Journal:  Life Sci Alliance       Date:  2022-05-05

9.  The expanding role of MRI in neuromuscular disorders.

Authors:  Pierre G Carlier; Harmen Reyngoudt
Journal:  Nat Rev Neurol       Date:  2020-06       Impact factor: 42.937

10.  Different Approaches to Analyze Muscle Fat Replacement With Dixon MRI in Pompe Disease.

Authors:  Alicia Alonso-Jiménez; Claudia Nuñez-Peralta; Paula Montesinos; Jorge Alonso-Pérez; Carme García; Elena Montiel; Izaskun Belmonte; Irene Pedrosa; Sonia Segovia; Jaume Llauger; Jordi Díaz-Manera
Journal:  Front Neurol       Date:  2021-07-08       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.